New research presented at this year’s European Congress on Obesity (ECO2026) in Istanbul, Turkey (12-15 May) and published in Nature Medicine shows that most weight loss achieved using the injectable obesity drugs tirzepatide or semaglutide can be maintained by switching to daily oral orforglipron treatment. The study is by Dr Louis J. Aronne, Director of the Comprehensive Weight Control Center at Weill Cornell Medicine, New York, New York, USA, and colleagues, and is sponsored by Eli Lilly and Company, the manufacturer of tirzepatide and orforglipron.

The discovery of their leading drug candidate, named T111, has been 15 years in the making and has the potential to become a single-encounter malaria drug that would simplify treatment, prevent relapses that drive ongoing transmission and contribute meaningfully to malaria elimination efforts.

Monoclonal antibodies can block a key immune‑related protein that drives the spread of brain cell damage in Parkinson’s disease (PD). This protein, called glycoprotein nonmetastatic melanoma B (GPNMB), might be part of a promising strategy for developing a treatment that slows disease progression at its earliest stages, according to a new study published today in Neuron, from researchers at the Perelman School of Medicine at the University of Pennsylvania. 

Mayo Clinic announced that President and CEO Gianrico Farrugia, M.D., has decided to complete his tenure at the end of this year.

Building on previous findings, researchers are exploring how desynchronized circadian rhythms may trigger brain inflammation associated with dementia risk.

Teens in disadvantaged neighborhoods are more likely to smoke, but it depends on whether they live in rural or urban areas.